Gileads escapes liability in hepatitis C patent fight with Merck

A U.S. judge on Monday found a pattern of misconduct by Merck & Co including lying under oath and other unethical practices, freeing Gilead Sciences Inc from paying any damages for infringing Merck’s patents with its lucrative treatments for hepatitis C, Sovaldi and Harvoni.

Read more.

Related

JOIN THE DISCUSSION